Aundhia Chintan, Parmar Ghanshyam, Talele Chitrali, Shah Niyati, Talele Dipali
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara, 391760, Gujarat, India.
School of Pharmacy, Vishwakarma University, Survey No. 2,3,4 Laxmi Nagar, Kondhwa Budruk, Pune, India.
Curr Top Med Chem. 2024 Aug 12. doi: 10.2174/0115680266324522240725053634.
This review explores the transformative impact of AI on drug development and delivery in pharmaceutical sciences, spanning formulation design, real-time monitoring, targeted delivery, and future prospects. The rational design of smart drug carriers, such as AI-optimized liposomes for cancer therapy, optimizes formulations for individual patient needs. AI-driven sensors, exemplified by glucose-monitoring biosensors for diabetics, enable adaptive drug administration, enhancing precision. Despite promises, challenges like biocompatibility, regulations, and ethics persist. Interdisciplinary collaboration and transparent communication are crucial for responsible AI adoption. Anticipated trends include personalized dosage optimization and intelligent nanocarriers. The review underscores AI's potential in reshaping pharmaceuticals for patient-centric care while addressing challenges for widespread adoption.
本综述探讨了人工智能对制药科学中药物开发和递送的变革性影响，涵盖制剂设计、实时监测、靶向递送及未来前景。智能药物载体的合理设计，如用于癌症治疗的人工智能优化脂质体，可根据个体患者需求优化制剂。以糖尿病患者的葡萄糖监测生物传感器为例的人工智能驱动传感器，能够实现适应性给药，提高精准度。尽管前景广阔，但生物相容性、法规和伦理等挑战依然存在。跨学科合作和透明沟通对于负责任地采用人工智能至关重要。预期趋势包括个性化剂量优化和智能纳米载体。该综述强调了人工智能在重塑以患者为中心的药物治疗方面的潜力，同时也应对了广泛应用所面临的挑战。
